Latest Content

In the second installment of this 2-part article on the WHO 2025 World Malaria Report, the authors point out the positive trends in the scaling up of prevention efforts with new-generation anti-mosquito netting, vaccines and periodic chemoprevention.

The WHO 2025 World Malaria Report adds several countries to those certified as malaria free, while recognizing spread of antimalarial drug resistance.

Amy Colson, MD, MPH, discusses phase 2 data showing durable virologic suppression, low resistance risk, and favorable safety with weekly oral islatravir plus lenacapavir in suppressed adults with HIV.

Gavin Harris, MD, discusses his experience working in outbreak environments where there is high-consequence infectious disease (HCID) and how it is important to establish buy-in from the local populations and some of the important elements of what you need to leave behind when an outbreak is declared over.

Agreement supports commercialization and reimbursement efforts for tobevibart plus elebsiran as the ECLIPSE clinical program advances, including completion of enrollment for the ECLIPSE 3 trial.

The single-source award will fund a large randomized trial evaluating mortality, morbidity, and developmental outcomes following the hepatitis B birth dose, amid ongoing debate over non-specific vaccine effects.

This week, learn more about Emory's approach around treating high-consequence infectious diseases such as Ebola, a UNC researcher's work in sequencing syphilis genomes in the search to develop a global vaccine, how the US is in danger of losing its elimination status for measles, and more.

Emory's Gavin Harris, MD, talks about taking care of patients with high-consequence infectious diseases, and considerations for not only their care, but their families. He also discusses working with other healthcare facilities around COVID-19 care and educating them through Emory's ECHO program on new and existing threats.

Zandraetta Tims-Cook, MD, MPH, AAHIVS, discusses access challenges, missed-dose management, and scalable care models for cabotegravir PrEP in women.

Jonathan Parr, MD, MPH, discusses his work in locating potential targets to develop a syphilis vaccine and the challenges associated with genomic diversity of subpopulations of the main pathogen, Treponema pallidum.

A Nature Microbiology study shows that structure-guided bile acid design can lock Clostridioides difficile toxin B into an inactive conformation, protecting mice from disease without disrupting the gut microbiome.

This new recommendation relates to infants born to women who test negative for hepatitis B. This is a departure from the federal agency’s previous recommendation and comes on the heels of the ACIP’s recent meeting.

Andrew Handel, MD, talks about transmission, differential diagnosis, treatment, and protection against it.